SAP insider Magazine
GxP-compliant environment within a 33-day delivery window. The reported scope included multiple plants and company codes, core finance integrated with Sage, procurement and materials management, planning and subcontract- ing, batch management and traceability, quality status management, inventory, and sales. Timelines of this nature are achievable only under specific conditions: disci- plined scope control, extensive reuse of prebuilt assets, tightly governed valida- tion processes, and sustained business availability throughout the delivery cy- cle. The relevance of the example lies not in its duration, but in what it illus- trates about where acceleration is pos- sible when regulatory rigor is treated as a design constraint rather than an after- thought. One mechanism that enables this kind of discipline is the use of in- dustry accelerators. Industry accelerators are often misun- derstood as one-size-fits-all solutions. In practice, their value lies in standard- izing what should be repeatable, while preserving flexibility where regulatory or business differentiation demands it. In life sciences, this typically includes preconfigured process flows, predefined user requirements, and traceability structures. These are aligned to regula- tory expectations such as the FDA’s 21 CFR Part 11, EU Annex 11 (where ap- plicable) risk-based initial security role designs that account for segregation- of-duties controls, and validation doc- umentation frameworks that support computer systems validation. Training and change assets are also increasingly delivered in a partially complete state, allowing programs to start from a gov- erned baseline rather than a blank page. Used correctly, these accelerators do not replace design work. They reduce re- work. The cycle-time benefit comes from eliminating the need to recreate artifacts that are already well understood, while ensuring changes are traceable from re- quirements through configuration and test evidence and that deviations are
orous documentation standards, and computer systems validation (CSV) requirements that traditionally extend project timelines. UST’s position is that disciplined use of templates, prebuilt artifacts, and automation can shorten delivery cycles while preserving regula- tory rigor. Accelerating SAP S/4HANA Delivery Faster SAP delivery claims are easiest to make in simple environments. They are hardest to substantiate in regulated industries, where validation, documen- tation, and auditability impose non- negotiable constraints. That is why life sciences frequently serves as a stress test for delivery models that promise speed without sacrificing control. One example, according to UST, is a KalVista Pharmaceuticals SAP S/4HANA implementation delivered to support a fixed commercial launch deadline. The system was implemented as a validated,
outputs are accepted or overridden. • AI-led work with human curation, where repeatable artifacts can be gen- erated quickly but must be reviewed by experienced practitioners. In this model, activities such as requirements refine- ment, role-matrix generation, docu- mentation production, and test content elements are automated first, then vali- dated (reviewed, approved, versioned, and traceable) by subject-matter experts to ensure accuracy and control. The design intent is to reduce time spent producing artifacts and redeploy scarce expertise toward decisions that influence scope, adoption, controls, and measurable business outcomes. That in- tent is easiest to articulate and hardest to prove in regulated environments, where delivery models are tested not just on functional outcomes but on documen- tation, validation, and auditability. UST frequently cites life sciences as proving ground for accelerated SAP delivery because of GxP controls, rig-
let’s connect sapinsider.org 75
Made with FlippingBook - Share PDF online